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Multiple Endocrine Neoplasia
1 Gene Alterations in
MEN1-Associated and
Sporadic Lipomas
Multiple endocrine neoplasia 1
(MEN1) syndrome is characterized by
the development of parathyroid adeno-
mas, pituitary adenomas, and duodenal
and/or pancreatic neuroendocrine tu-
mors. The vast majority, and possibly
all, of these tumors are characterized by
two genetic hits—germline mutation of
the MEN1 tumor suppressor gene com-
bined with allelic deletion of the corre-
sponding wild-type allele (1). Alter-
ations of the MEN1 gene are not only
found in MEN1-associated tumors but
also, with decreasing frequency, in spo-
radic neuroendocrine tumors of the fore-
gut (2,3), parathyroid tumors (4), and pi-
tuitary adenomas (5).
Lipomatous tumors are known to oc-
cur in a relatively high proportion of pa-
tients with MEN1 disease. In this study,
we attempted to determine the role of
the MEN1 gene in the development of
MEN1-associated and sporadic lipomas.
For genetic tissue analysis of MEN1-
associated lipomas, we obtained prepa-
rations by touching tumor tissue to a
glass slide to transfer a limited number
of cells; we then performed fluorescence
in situ hybridization (FISH) on such
touch preparations to detect deletions of
the MEN1 wild-type allele in two tu-
mors that were excised from two pa-
tients with known MEN1 gene germline
mutations (case 1—a 61-year-old male
with an abdominal wall lipoma, muta-
tion status L22R; case 2—a 69-year-old
male with a lipoma of the right thigh,
mutation status W436R). FISH was per-
formed using as a probe cosmid clone
c10B11 (size, 40 kilobases), which con-
tains the MEN1 gene (6). For analysis of
sporadic lipomas, we performed poly-
merase chain reaction (PCR)-based
single-strand conformation polymor-
phism and sequence analysis using for-
malin-fixed, paraffin-embedded tissue.
FISH analysis of the two lipomas,
which were excised from patients with
known MEN1 disease, revealed loss of
one MEN1 allele in 53% of the cells
examined from case 1 (Fig. 1, left panel)
and in 63% of the cells examined from
case 2. It appears from this finding that
the lipoma cells are affected by genetic
deletion, whereas both MEN1 gene cop-
ies were visualized in normal cellular
constituents. Furthermore, in both cases,
two copies of the chromosome 11 alpha
satellite, located in the centromere, were
present in all of the cells, as shown by a
control probe. In conjunction with a re-
cent PCR-based deletion analysis of
three lipomas (7), our results confirm
the hypothesis that mutation of the
MEN1 gene and subsequent loss of the
wild-type allele are associated with or
causative for the development of lipo-
matous tumors in patients with MEN1
disease.
To investigate the role of the MEN1
gene in sporadic lipomas, we analyzed
six sporadic tumors (female : male 4
2:4; mean age 4 33 ± 16 years). Lipo-
matous and normal control tissue was
scraped from sections of paraffin-
embedded tissue after deparaffinization
in xylene and alcohol. The removed tis-
sue was placed in proteinase K buffer
for DNA extraction. The DNA samples
were PCR amplified with 13 pairs of
markers amplifying the coding regions
of the MEN1 gene, including exons 2–
10, as previously described (2). The am-
plification products were visualized af-
ter polyacrylamide gel electrophoresis.
Due to poor tissue quality, amplification
products were only obtained for exons 2,
3, 8, and 9. In one case, single-strand
conformation polymorphism analysis
and subsequent sequence analysis re-
vealed a four-nucleotide deletion in
exon 2 (Fig. 1, right panel). This dele-
tion was present only in the tumor tissue
but not in the normal tissue control from
the same patient. From this finding, we
conclude that MEN1 gene mutation may
play a role not only in the development
of MEN1-associated lipomas but also in
sporadic lipomas.
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Fig. 1. Detection of genetic alterations in multiple endocrine neoplasia 1 (MEN1)-associated and sporadic
lipomas. Left panel) fluorescence in situ hybridization analysis of a preparation, obtained by touching
tumor tissue to a glass slide to transfer a limited number of cells, from lipomatous tissue (case 1) using
cosmid clone c10B11, which contains the MEN1 gene as a probe; red signals 4 the presence of the MEN1
gene on chromosome 11q13, green signals 4 the centromeric region of chromosome 11; four cells exhibit
loss of one MEN1 allele; one cell in the right upper corner shows the presence of both MEN1 gene copies,
and therefore is interpreted as a non-neoplastic stromal cell. Right panel) Sequence analysis of a sporadic
lipoma (case 1) reveals a TGTC deletion in the tumor cells when compared with normal control tissue
from the same patient.
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Re: Prevalence of Cancer
A recent Stat Bite (1) showed the
prevalent cases of eight cancer types in
the U.S. population. Practitioners of
public health often ignore prevalence as
a measure of disease frequency, prob-
ably because differences in prevalence
between groups can arise from differ-
ences in incidence or from differences in
the average survival (2). While this am-
biguity may cloud etiologic interpreta-
tion of differences in prevalence, the
mixture of occurrence and survival
makes prevalence an important measure
of the distribution of disease.
Fig. 1 shows our estimates of the
prevalence, prevalent cases, and annual
incident cases of breast cancer by age
among U.S. women in 1997. We esti-
mated the prevalence by applying the
method of Alho (3) to data reported by
the National Cancer Institute (NCI) (4),
the National Center for Health Statistics,
and the Census Bureau. A further de-
scription is available from the authors.
The age-specific prevalence provides
insight into the distribution of breast
cancer among U.S. women. This insight
differs from what one would learn by
examining incidence rates alone. For ex-
ample, while about 22% of incident
cases of breast cancer occur in women
younger than age 50 years, only about
12% of the prevalent cases exist in that
group. Similarly, 51% of new cases oc-
cur in women younger than age 65
years, but only about 42% of the preva-
lent cases exist in that group. The ratio
of the number of prevalent cases to an-
nual incident cases increases in older
age groups. Among women 40–44 years
old, the ratio of prevalent cases to an-
nual incident cases is about 6 to 1.
Among women 70–74 years old, the ra-
tio is about 12 to 1.
This description of prevalent breast
cancer emphasizes the importance of in-
cluding the elderly population in studies
of cancer survivors. There are about as
many prevalent cases of breast cancer
among women ages 80–84 years as
there are among women ages 55–59
years. Women may weigh aspects of
cancer treatment and survival differently
depending on their age. For example,
younger women are often concerned
about the effect of treatment on their
ability to meet their obligations, such as
caring for family members (5). About
20% of the women less than 75 years old
at diagnosis said this was a very impor-
tant consideration in making decisions
about treatment for breast cancer.
Among women age 75 years and older,
7% said this was a very important con-
sideration and 83% said it was not im-
portant at all. Younger women may
weight most heavily the expected dura-
tion of survival, whereas older women
may weight most heavily the quality of
their expected survival, particularly their
ability to live independently. The elderly
have often been excluded from studies of
treatment efficacy, and the frequency of
age-related exclusion has increased in re-
cent years (6), at least in the case of acute
myocardial infarction. As the NCI em-
barks on a formal program to study cancer
survivors (7), the program must take care
to avoid a reprise of this ageist history.
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Fig. 1. Estimated prevalence, number of prevalent cases, and annual number of incident cases of breast
cancer among U.S. women in 1997.
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